Cited by 406Ovarian cancer diagnosis and treatmentCancer Cells and MetastasisOvarian function and disorders

The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.

Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes

Open access

Beaufort, Corine M., Helmijr, Jean C. A., Piskorz, Anna M., Hoogstraat, Marlous, Ruigrok-Ritstier, Kirsten, Besselink, Nicolle, Murtaza, Muhammed, van IJcken, Wilfred F. J., Heine, Anouk A. J., Smid, Marcel, Koudijs, Marco J., Brenton, James D., Berns, Els M. J. J., Helleman, Jozien·2014·PLoS ONE

DOI 10.1371/journal.pone.0103988PMC PMC4167545

Open this paper in CoChat — free account Open PDF

Abstract

Epithelial ovarian cancer is a highly heterogeneous disease and remains the most lethal gynaecological malignancy in the Western world. Therapeutic approaches need to account for inter-patient and intra-tumoural heterogeneity and detailed characterization of in vitro models representing the different histological and molecular ovarian cancer subtypes is critical to enable reliable preclinical testing. There are approximately 100 publicly available ovarian cancer cell lines but their cellular and molecular characteristics are largely undescribed. We have characterized 39 ovarian cancer cell lines under uniform conditions for growth characteristics, mRNA/microRNA expression, exon sequencing, drug response for clinically-relevant therapeutics and collated all available information on the original clinical features and site of origin. We tested for statistical associations between the cellular and molecular features of the lines and clinical features. Of the 39 ovarian cancer cell lines, 14 were assigned as high-grade serous, four serous-type, one low-grade serous and 20 non-serous type. Three morphological subtypes: Epithelial (n = 21), Round (n = 7) and Spindle (n = 12) were identified that showed distinct biological and molecular characteristics, including overexpression of cell movement and migration-associated genes in the Spindle subtype. Comparison with the original clinical data showed association of the spindle-like tumours with metastasis, advanced stage, suboptimal debulking and poor prognosis. In addition, the expression profiles of Spindle, Round and Epithelial morphologies clustered with the previously described C1-stromal, C5-mesenchymal and C4 ovarian subtype expression profiles respectively. Comprehensive profiling of 39 ovarian cancer cell lines under controlled, uniform conditions demonstrates clinically relevant cellular and genomic characteristics. This data provides a rational basis for selecting models to develop specific treatment approaches for histological and molecular subtypes of ovarian cancer.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0103988

Cites

90 of 90 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Integrative genomics viewer
Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390 · cited 1×
“Sequence analysis and variant verification was performed as described previously [26,27].”
Method
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950 · cited 1×
“analysed genomic data for 47 ovarian cancer cell lines from the CCLE collection [13] for genetic similarity to highgrade serous ovarian carcinomas from the TCGA data [4,57].”
Background
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
Cancer Genome Landscapes
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Comprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
The Massachusetts Institute of Technology
Endowed, S. C. F. (1999) · Anthropology News · doi:10.1111/an.1999.40.2.6 · Cited by 3,132
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456 · cited 1×
“Worldwide, there are about 100 ovarian cancer cell lines generated as described in literature [12–17] and about 70 of these are available at ATCC, ECACC, RIKEN, DSMZ, JCRB or Cancer Research Technology.”
Background
One Hundred and Twenty-Seven Cultured Human Tumor Cell Lines Producing Tumors in Nude Mice23
Fogh, J., Fogh, J. M., & Orfeo, T. (1977) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/59.1.221 · Cited by 1,599
Rethinking ovarian cancer: recommendations for improving outcomes
Vaughan, S., Coward, J. I. G., Bast, R. C., Berchuck, A., Berek, J. S., Brenton, J. D., Coukos, G., Crum, C. P., Drapkin, R., Etemadmoghadam, D., et al. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3144 · Cited by 1,484 · cited 1×
“The remaining histiotypes are mucinous, endometrioid and clear cell [3].”
Background
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
Tothill, R. W., Tinker, A. V., George, J., Brown, R. E., Fox, S. B., Lade, S., Johnson, D., Trivett, M. K., Etemadmoghadam, D., Locandro, B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0196 · Cited by 1,458 · cited 7×
“We used the expression data for 267 malignant ovarian carcinomas (GSE9891) [11] to determine the clinical significance of the morphological subtypes seen in our cell lines.”
BackgroundMethodInfluential

Flagged first, then by citations

Show all 89 references

Sorted by citations

Items 201–300 of 406

Suppression of autophagy enhances preferential toxicity of epothilone A and epothilone B in ovarian cancer cells
Rogalska, A., Gajek, A., & Marczak, A. (2019) · Phytomedicine · doi:10.1016/j.phymed.2019.152847 · Cited by 16
Oncogenic Role of miR-200c-3p in High-Grade Serous Ovarian Cancer Progression via Targeting the 3′-Untranslated Region of DLC1
Ankasha, S. J., Shafiee, M. N., Wahab, N. A., Ali, R. A. R., & Mokhtar, N. M. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18115741 · Cited by 16
“However, the genetic analysis showed that SKOV3 not only had a mutation on TP53, but also in ARID1A, where it was most likely to be endometrioid or clear cell carcinoma [37,38].”
Background
The Enhanced Efficacy of Intracellular Delivery of Doxorubicin/C6-Ceramide Combination Mediated by the F3 Peptide/Nucleolin System Is Supported by the Downregulation of the PI3K/Akt Pathway
Cruz, A. F., Biscaia-Caleiras, M., Fonseca, N. A., Gonçalves, N., Mendes, V. M., Sampaio, S. F., Moura, V., Melo, J. B., Almeida, R. D., Manadas, B. J., et al. (2021) · Cancers · doi:10.3390/cancers13123052 · Cited by 16
“Herein, it was demonstrated by Western blot that nucleolin was overexpressed in the cytoplasm and cell membrane (Figure 1B) of cell lines derived from different sub-types of patient-derived ovarian cancer as endometrioid ovarian carcinoma (TOV-112D) and high-grade serous ovarian carcinoma (OVCAR-3 and SKOV-3) [43], si…”
Result
A Systematic Comparative Assessment of the Response of Ovarian Cancer Cells to the Chemotherapeutic Cisplatin in 3D Models of Various Structural and Biochemical Configurations—Does One Model Type Fit All?
Gupta, P., Miller, A. F., Olayanju, A., Madhuri, T. K., & Velliou, E. G. (2022) · Cancers · doi:10.3390/cancers14051274 · Cited by 18
Active Hexose Correlated Compound (AHCC) Inhibits the Proliferation of Ovarian Cancer Cells by Suppressing Signal Transducer and Activator of Transcription 3 (STAT3) Activation
Choi, J., Lee, S., Yun, S.-M., Suh, D. H., Kim, K., No, J. H., Jeong, E.-H., & Kim, Y. B. (2017) · Nutrition and Cancer · doi:10.1080/01635581.2018.1380203 · Cited by 17
“CAOV3 cells originated from epithelial ovarian cancer tissue, and OV90 cells were derived from high-grade serous ovarian carcinoma from ascites (19).”
Background
Next Generation of Ovarian Cancer Detection Using Aptamers
Abreu, R. D. S., Antunes, D., Moreira, A. D. S., Passetti, F., Mendonça, J. B., de Araújo, N. S., Sassaro, T. F., Alberto, A. V. P., Bastos, N. C., Fernandes, P. V., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076315 · Cited by 15
“This is the most frequent, accounting for 80% of cases, and still the most aggressive among ovarian tumor types [21].”
Background
The role and impact of alternative polyadenylation and miRNA regulation on the expression of the multidrug resistance-associated protein 1 (MRP-1/ABCC1) in epithelial ovarian cancer
Marjamaa, A., Gibbs, B. E., Kotrba, C., & Masamha, C. P. (2023) · Scientific Reports · doi:10.1038/s41598-023-44548-y · Cited by 15
Integrated transcriptomic and proteomic analysis identifies protein kinase CK2 as a key signaling node in an inflammatory cytokine network in ovarian cancer cells
Kulbe, H., Iorio, F., Chakravarty, P., Milagre, C. S., Moore, R., Thompson, R. G., Everitt, G. L. A., Canosa, M., Montoya, A., Drygin, D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7255 · Cited by 14
“However, the widely used cell lines SKOV-3 and IGROV-1 were implicated as not being representative of the major HGSC subtype [14-16].”
A Unique Pattern of Mesothelial-Mesenchymal Transition Induced in the Normal Peritoneal Mesothelium by High-Grade Serous Ovarian Cancer
Pakuła, M., Uruski, P., Niklas, A. A., Woźniak, A., Szpurek, D., Tykarski, A., Mikuła‐Pietrasik, J., & Książek, K. (2019) · Cancers · doi:10.3390/cancers11050662 · Cited by 15
“Therefore, we designed a study in which we compared the ability of A2780 and SKOV-3 cells, which represent less aggressive endometrioid/clear cell histotypes, and of OVCAR-3 and primary EOCs, which are aggressive high-grade serous ovarian carcinomas (HGSOCs) [9], to induce MMT.”
BackgroundResultInfluential
Modeling the Diversity of Epithelial Ovarian Cancer through Ten Novel Well Characterized Cell Lines Covering Multiple Subtypes of the Disease
Sauriol, S. A., Simeone, K., Portelance, L., Meunier, L., Leclerc-Desaulniers, K., de Ladurantaye, M., Chergui, M., Kendall‐Dupont, J., Rahimi, K., Carmona, E., et al. (2020) · Cancers · doi:10.3390/cancers12082222 · Cited by 15
“Moreover, systematic genomic and morphological analyses of a panel of the most often used ovarian cancer cell lines suggested that most of these cell lines were unlikely to originate from HGSC [34,35,97] and, thus, are inadequate models for studying this disease.”
ONC201 induces the unfolded protein response (UPR) in high‐ and low‐grade ovarian carcinoma cell lines and leads to cell death regardless of platinum sensitivity
Rumman, M., Buck, S. A., Polin, L., Dzinic, S. H., Boerner, J. L., & Winer, I. S. (2021) · Cancer Medicine · doi:10.1002/cam4.3858 · Cited by 14
Reduced RBPMS Levels Promote Cell Proliferation and Decrease Cisplatin Sensitivity in Ovarian Cancer Cells
Rabelo-Fernández, R. J., Santiago-Sánchez, G. S., Sharma, R. K., Roche-Lima, A., Carrasquillo, K., Rivera, R. A. N., Quiñones‐Díaz, B. I., Rajasekaran, S., Siddiqui, J., Miles, W. O., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23010535 · Cited by 14
“A2780 cells are classified as clear cell carcinomas, while OVCAR3 cells are HGSOCs [24,25].”
Background
Characteristics of Extracellular Vesicles from a High-Grade Serous Ovarian Cancer Cell Line Derived from a Platinum-Resistant Patient as a Potential Tool for Aiding the Prediction of Responses to Chemotherapy
Černe, K., Kelhar, N., Resnik, N., Herzog, M., Vodnik, L., Veranič, P., & Kobal, B. (2023) · Pharmaceuticals · doi:10.3390/ph16060907 · Cited by 13
“The examination of the BRCA1 status yielded contradictory results; a BRCA1 mutation was detected in one study, but this result was not confirmed in two other studies [33,34,44].”
BackgroundMethodResultInfluential
Targeting carcinoma‐associated mesothelial cells with antibody–drug conjugates in ovarian carcinomatosis
Pascual‐Antón, L., Sandoval, P., Gónzalez-Mateo, G. T., Kopytina, V., Tomero‐Sanz, H., Arriero‐País, E. M., Jiménez-Heffernan, J. A., Fabre, M., Egaña, I., Ferrer, C., et al. (2023) · The Journal of Pathology · doi:10.1002/path.6170 · Cited by 14
Mechanisms of carboplatin‐ and paclitaxel‐dependent induction of premature senescence and pro‐cancerogenic conversion of normal peritoneal mesothelium and fibroblasts
Rutecki, S., Pakuła‐Iwańska, M., Leśniewska-Bocianowska, A., Matuszewska, J., Rychlewski, D., Uruski, P., Stryczyński, Ł., Naumowicz, E., Szubert, S., Tykarski, A., et al. (2023) · The Journal of Pathology · doi:10.1002/path.6223 · Cited by 14
“This effect is universal and not associated with any speci ﬁ c feature, as the cells used in the study represent different histotypes, molecular pro ﬁ les, and stages of the disease [52,53].”
Background
The HMGB1-2 Ovarian Cancer Interactome. The Role of HMGB Proteins and Their Interacting Partners MIEN1 and NOP53 in Ovary Cancer and Drug-Response
Cámara-Quílez, M., Barreiro-Alonso, A., Vizoso‐Vázquez, Á., Rodriguez-Belmonte, E. M., Varela, M. Q., Maceiras, M. L., & Cerdán, M. E. (2020) · Cancers · doi:10.3390/cancers12092435 · Cited by 14
“MIEN1 and NOP53 by co-immunoprecipitation, an orthogonal method to the Y2H approach, and using two EOC cell lines, SKOV-3 and PEO1 representatives of ENOC/CCOC and HGSOC respectively [33].”
Method
Suicide gene strategies applied in ovarian cancer studies
Nguyen, Q. M., Dupré, P., Haute, T., Montier, T., & d’Arbonneau, F. (2023) · Cancer Gene Therapy · doi:10.1038/s41417-023-00590-6 · Cited by 20
MUL1 E3 ligase regulates the antitumor effects of metformin in chemoresistant ovarian cancer cells via AKT degradation
Lee, J., An, S., Jung, J. H., Kim, K., Kim, J. E., An, I., & Bae, S. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4730 · Cited by 14
Constructing a co-culture model of cancer-associated fibroblasts and ovarian cancer organoids and studying mechanisms of drug resistance
Ma, X., Xue, F., Pei, Z., & Zhao, Y. (2025) · Experimental Cell Research · doi:10.1016/j.yexcr.2025.114656 · Cited by 13
Functional Homologous Recombination (HR) Screening Shows the Majority of BRCA1/2-Mutant Breast and Ovarian Cancer Cell Lines Are HR-Proficient
Meijer, T. G., Martens, J. W. M., der Smissen, W. J. C. P., Verkaik, N. S., Beaufort, C. M., van Herk, S., Robert-Finestra, T., Hoogenboezem, R. M., Ruigrok-Ritstier, K., Paul, M. W., et al. (2024) · Cancers · doi:10.3390/cancers16040741 · Cited by 13
“Gene expression data for part of the BC and OC cell lines ( n = 69) were generated previously (GSE9385 and GSE53418) and measured using the Affymetrix GeneChip Human Exon 1.0 ST Array [25,37].”
MethodInfluential
Improving cellular analysis throughput of lens-free holographic microscopy with circular Hough transform and convolutional neural networks
Pala, M. A., & Yıldız, M. Z. (2024) · Optics & Laser Technology · doi:10.1016/j.optlastec.2024.110920 · Cited by 13
Sphingomyelin synthase 2 but not sphingomyelin synthase 1 is upregulated in ovarian cancer and involved in migration, growth and survival via different mechanisms.
Jing, F., Jing, C., Dai, X., Zhou, G., Di, S., Bi, X., Dai, T., Qin, T., & Hong, L. (2021) · PubMed Central · Cited by 13
The anti-tumor effect of OP-B on ovarian cancer in vitro and in vivo, and its mechanism: An investigation using network pharmacology-based analysis
Yuan, S., Xu, Y., Yi, T., & Wang, H. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114706 · Cited by 13
Unraveling Autocrine Signaling Pathways through Metabolic Fingerprinting in Serous Ovarian Cancer Cells
Ha, J. H., Jayaraman, M., Nadhan, R., Kashyap, S., Mukherjee, P., Isidoro, C., Song, Y. S., & Dhanasekaran, D. N. (2021) · Biomedicines · doi:10.3390/biomedicines9121927 · Cited by 15
“Utilizing genomic profiling, previous studies have contributed significantly in identifying ovarian cancer cell lines that closely resemble ovarian cancer tissues [51,52].”
Background
Destabilizers of the thymidylate synthase homodimer accelerate its proteasomal degradation and inhibit cancer growth
Costantino, L., Ferrari, S., Santucci, M., Salo‐Ahen, O. M. H., Carosati, E., Franchini, S., Lauriola, A., Pozzi, C., Trande, M., Gozzi, G., et al. (2022) · eLife · doi:10.7554/elife.73862 · Cited by 13
Genetic Perturbation of Pyruvate Dehydrogenase Kinase 1 Modulates Growth, Angiogenesis and Metabolic Pathways in Ovarian Cancer Xenografts
Venturoli, C., Piga, I., Curtarello, M., Verza, M., Esposito, G., Venuto, S., Navaglia, F., Grassi, A., & Indraccolo, S. (2021) · Cells · doi:10.3390/cells10020325 · Cited by 14
“In fact, while OVCAR3 is recognized as an almost certain model of high grade serous ovarian cancer [29,30], OC316 has an hypermutated genotype and uncertain histologic origin [31].”
Background
PFKFB3 Inhibition Sensitizes DNA Crosslinking Chemotherapies by Suppressing Fanconi Anemia Repair
Ninou, A. H., Lehto, J., Chioureas, D., Stigsdotter, H., Schelzig, K., Åkerlund, E., Gudoitytė, G., Joneborg, U., Carlson, J. W., Jonkers, J., et al. (2021) · Cancers · doi:10.3390/cancers13143604 · Cited by 11
“Here, we identify a cancer-specific synthetic lethality between PFKFB3 and platinum drugs treatment including restoring sensitivity to platinum in resistant cell models, independent of p53 and BRCA2 mutational status [63] (Figure 1).”
Background
Cytotoxic effects of halophilic archaea metabolites on ovarian cancer cell lines
Kowalewicz‐Kulbat, M., Krawczyk, K. T., Szulc-Kiełbik, I., Rykowski, S., Denel‐Bobrowska, M., Olejniczak, A. B., Locht, C., & Klink, M. (2023) · Microbial Cell Factories · doi:10.1186/s12934-023-02206-y · Cited by 12
“…three ovarian cancer cell lines frequently used to study ovarian carcinoma: the cisplatin-sensitive ovarian tumor cell line A2780 and the corresponding cisplatin-resistant A2780cis cell line, as well as the cisplatin-resistant and highly invasive SK-OV-3 cell line, originating from ascites [21–23].”
Background
Cell-intrinsic platinum response and associated genetic and gene expression signatures in ovarian cancer
Adams, K. M., Wendt, J.-R., Wood, J., Olson, S. L., Moreno, R., Jin, Z., Gopalan, S., & Lang, J. D. (2025) · Cancer Gene Therapy · doi:10.1038/s41417-025-00941-5 · Cited by 12
Chemosensitivity of various peritoneal cancer cell lines to HIPEC and PIPAC: comparison of an experimental duplex drug to standard drug regimens in vitro
Weinreich, J., Struller, F., Sautkin, I., Giuashvili, S., Reymond, M. A., Königsrainer, A., & Schott, T. C. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0641-6 · Cited by 12
Long Intergenic Noncoding RNA OIN1 Promotes Ovarian Cancer Growth by Modulating Apoptosis-Related Gene Expression
Takeiwa, T., Mitobe, Y., Ikeda, K., Hasegawa, K., Horie, K., & Inoue, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011242 · Cited by 12
“Regarding the cells used in this study, OV90 and OVCAR3 cells are derived from high-grade serous carcinoma while ES2 cells are derived from clear cell carcinoma, and the histological subtypes from which A2780 and SKOV3 originate remain controversial [25,26].”
BackgroundInfluential
Characterization and drug sensitivity of a novel human ovarian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor
Franklin, M., Gentles, L., Matheson, E. C., Bown, N. P., Cross, P., Ralte, A. M., Gilkes‐Immeson, C., Bradbury, A., Zanjirband, M., Lunec, J., et al. (2018) · Cancer Medicine · doi:10.1002/cam4.1724 · Cited by 12
Adaptive therapy for ovarian cancer: An integrated approach to PARP inhibitor schedulingPreprint
Strobl, M. A. R., Martin, A. L., West, J., Gallaher, J. A., Robertson‐Tessi, M., Gatenby, R. A., Wenham, R. M., Maini, P. K., Damaghi, M., & Anderson, A. R. A. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.03.22.533721 · Cited by 12
Mechanomimetic 3D Scaffolds as a Humanized In Vitro Model for Ovarian Cancer
Paradiso, F., Lenna, S., Gazze, S. A., García-Parra, J., Murphy, K., Margarit, L., González, D., Francis, L. W., & Taraballi, F. (2022) · Cells · doi:10.3390/cells11050824 · Cited by 11
“OVCAR-3 and Caov-3 possess TP53 mutations and substantial copy-number changes, which are key characteristics of HGSC, whereas SKOV3, based on its genetic profile, is categorized as non-serous [106,107].”
Background
Single-Cell ICP-MS in Combination with Fluorescence-Activated Cell Sorting for Investigating the Effects of Nanotransported Cisplatin(IV) Prodrugs
Gutierrez-Romero, L., Blanco‐González, E., & Montes‐Bayón, M. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.3c02506 · Cited by 11
Proteomic and Phosphoproteomic Reprogramming in Epithelial Ovarian Cancer Metastasis
Frederick, M. I., Hovey, O. F. J., Kakadia, J. H., Shepherd, T. G., Li, S. S. ‐., & Heinemann, I. U. (2023) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2023.100660 · Cited by 11
“Indeed, OVCAR8 cells are known to overexpress cell movement and migration-associated genes (46, 47), making them ideal for studying the metastasis process.”
Background
Loss of XIST lncRNA unlocks stemness and cellular plasticity in ovarian cancer
Naciri, I., Liang, M., Yang, Y., Karner, H. M., Lin, B., Ludena, M. D. L. A., Hanse, E. A., Lebron, A., Razorenova, O. V., Nicholas, D., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2418096121 · Cited by 10
Genomic, Transcriptomic, and Functional Alterations in DNA Damage Response Pathways as Putative Biomarkers of Chemotherapy Response in Ovarian Cancer
Saha, S. S., Gentles, L., Bradbury, A., Brecht, D., Robinson, R., O'Donnell, R. L., Curtin, N. J., & Drew, Y. (2021) · Cancers · doi:10.3390/cancers13061420 · Cited by 10
“Several earlier studies have attempted to analyse the genomic/transcriptomic/histological sub-type characterisation of ovarian cancer cell lines or correlate with response to chemotherapy [12,22,23].”
In vitro evaluation of the pogostone effects on the expression of PTEN and DACT1 tumor suppressor genes, cell cycle, and apoptosis in ovarian cancer cell line
Homayoun, M., Sajedi, N., & Soleimani, M. (2022) · Research in Pharmaceutical Sciences · doi:10.4103/1735-5362.335175 · Cited by 11
“Extensive studies on 39 ovarian cancer cell lines including OVCAR-3 have shown that PTEN and DACT1 tumor suppressor genes were the wild-type form (24).”
Background
Rab11a promotes the malignant progression of ovarian cancer by inducing autophagy
Wang, Y., Ren, Y., Li, N., Zhao, J., & Zhao, S. (2022) · Genes & Genomics · doi:10.1007/s13258-022-01314-0 · Cited by 11
“1 3 A2780 cells were obtained from tumor tissues of unspecified histological classification, and their histological subtype was presumed to be endometrioid (Beaufort et al. 2014).”
Background
Three-Dimensional Collagen Topology Shapes Cell Morphology, beyond Stiffness
Chen, C., Ibrahim, Z., Marchand, M. F., Piolot, T., Kamboj, S., Carreiras, F., Yamada, A., Schanne‐Klein, M., Chen, Y., Lambert, A., et al. (2022) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.2c00879 · Cited by 11
Visfatin increases the invasive potential of ovarian granulosa tumor spheroids by reprogramming glucose metabolism
Gogola-Mruk, J., Marynowicz, W., Krawczyk, K., & Ptak, A. (2023) · Reproduction · doi:10.1530/rep-22-0443 · Cited by 11
Histone deacetylase inhibitor induced pVHL-independent degradation of HIF-1α and hierarchical quality control of pVHL via chaperone system
Ni, J., & Anping, N. (2021) · PLoS ONE · doi:10.1371/journal.pone.0248019 · Cited by 11
“To date, preclinical studies have demonstrated that combination of HDACi with conventional cytotoxic regimens could be effective for patients with relapsed ovarian cancer, which also resulted in a significant regression of lesion in xenograft model of high grade serous carcinoma (HGSC) [23, 24].”
Background
Metabolomics profiling and chemoresistance mechanisms in ovarian cancer cell lines: Implications for targeting glutathione pathway
Alarcón, P., Pérez, A. J., Toledo, K., Contreras, H., Ormazábal, V., Nova‐Lamperti, E., Aguayo, C. R., Salomón, C., & Zuñiga, F. A. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122166 · Cited by 10
Truncated isoform Vav3.1 is highly expressed in ovarian cancer stem cells and clinically relevant in predicting prognosis and platinum‐response
Reimer, D., Boesch, M., Wolf, D. G. F., Marth, C., Sopper, S., Hatina, J., Altevogt, P., Parson, W., Hackl, H., & Zeimet, A. G. (2017) · International Journal of Cancer · doi:10.1002/ijc.31186 · Cited by 10
Spirocyclic dimer SpiD7 activates the unfolded protein response to selectively inhibit growth and induce apoptosis of cancer cells
Kour, S., Rana, S., Kubica, S. P., Kizhake, S., Ahmad, M., Muñoz-Trujillo, C., Klinkebiel, D. L., Singh, S., Mallareddy, J. R., Chandra, S., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101890 · Cited by 10
“Next, to determine the relative potency of the SpiD7 and 19 to inhibit growth of HGSC cell lines (47, 48), we subjected them to a 3-day cell growth assay.”
Method
Impairment of RAD17 Functions by miR-506-3p as a Novel Synthetic Lethal Approach Targeting DNA Repair Pathways in Ovarian Cancer
Bagnoli, M., Nicoletti, R., Valitutti, M., Rizzo, A., Napoli, A., Montalvão-de-Azevedo, R., Tomassetti, A., & Mezzanzanica, D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.923508 · Cited by 10
Microfibril Associated Protein 5 (MFAP5) Is Related to Survival of Ovarian Cancer Patients but Not Useful as a Prognostic Biomarker
Kujawa, K. A., Zembala‐Nożyńska, E., Syrkis, J. P., Cortez, A. J., Kupryjańczyk, J., & Lisowska, K. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415994 · Cited by 10
“The OAW42 line is relatively popular and has been re-evaluated according to its originally quoted histological origin in several recent studies [29,30]; reviewed in [31].”
Background
A Cell-Autonomous Oncosuppressive Role of Human RNASET2 Affecting ECM-Mediated Oncogenic Signaling
Roggiani, F., Riva, C., Raspagliesi, F., Porta, G., Valli, R., Taramelli, R., Acquati, F., Mezzanzanica, D., & Tomassetti, A. (2019) · Cancers · doi:10.3390/cancers11020255 · Cited by 10
“The RNASET2-expressing OAW42 EOC cell line, displaying an epithelial morphology [18,19], was stably silenced for RNASET2 expression by RNA interference.”
Background
Development of a near infrared protein nanoprobe targeting Thomsen-Friedenreich antigen for intraoperative detection of submillimeter nodules in an ovarian peritoneal carcinomatosis mouse model
Coustets, M., Ladurantie, C., Bellard, E., Prat, M., Rols, M., Ecochard, V., Ferron, G., Chabot, S., Golzio, M., & Paquereau, L. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.119908 · Cited by 10
“Regarding EOC, the MUC16 glycoprotein and its circulating form (CA125) are the standard FDA approved biomarkers.”
BackgroundInfluential
Ruthenium tetrazene complexes bearing glucose moieties on their periphery: Synthesis, characterization, and in vitro cytotoxicity
Hamala, V., Martišová, A., Šťastná, L. Č., Karban, J., Dančo, A., Šimarek, A., Lamač, M., Horáček, M., Kolářová, T., Hrstka, R., et al. (2020) · Applied Organometallic Chemistry · doi:10.1002/aoc.5896 · Cited by 10
Functional Analyses of RUNX3 and CaMKIINα in Ovarian Cancer Cell Lines Reveal Tumor-Suppressive Functions for CaMKIINα and Dichotomous Roles for RUNX3 Transcript Variants
Heinze, K., Kritsch, D., Mosig, A. S., Dürst, M., Häfner, N., & Runnebaum, I. B. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010253 · Cited by 10
“Cell line authentication was done by STR profiling in September 2014 and February 2016 and revealed the correct identity depicted by a 97 % and 100 % match for A2780 and SKOV3 (ICLAC Match Criteria Worksheet [44]) compared to STR reference profiles (ATCC and [45]).”
Result
High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma
Hollis, R. L., Elliott, R. J. R., Dawson, J. C., Ilenkovan, N., Matthews, R., Stillie, L. J., Oswald, A. J., Kim, H. H., Llauradó, M., Churchman, M., et al. (2024) · Gynecologic Oncology · doi:10.1016/j.ygyno.2024.03.029 · Cited by 9
“HOC7 is known to harbour a KRAS G12A mutation (table S1), as previously described [21].”
Background
Distinct effects of sacituzumab govitecan and berzosertib on DNA damage response in ovarian cancer
Nair, J. R., Huang, T., Sunkara, A. D., Pruitt, M. R., Ibanez, K. R., Chiang, C.-Y., Cheng, K. C.-C., Wilson, K. M., Cardillo, T. M., Hofsess, S. J., et al. (2024) · iScience · doi:10.1016/j.isci.2024.111283 · Cited by 9
“18 The linker allows the intra-tumoral release of therapeutic concentrations of iScience Article ll OPEN ACCESS SN-38, as well as extracellular release within the surrounding tumor microenvironment, providing a bystander effect.”
Family with sequence similarity 46 member a confers chemo-resistance to ovarian carcinoma via TGF-β/Smad2 signaling
Liang, S., Liu, Y.-Y., He, J., Gao, T. M., Li, L., & He, S. (2022) · Bioengineered · doi:10.1080/21655979.2022.2064652 · Cited by 9
CCNE1 is a potential target of Metformin for tumor suppression of ovarian high-grade serous carcinoma
Mei, J., Tian, H., Huang, H.-S., Wu, N., Liou, Y., Chu, T., Wang, J., & Zhang, W. (2022) · Cell Cycle · doi:10.1080/15384101.2022.2109362 · Cited by 9
“Beaufort showed that p53 was considered the key gene in the transformation of ovarian cancer, and the mutations of myc, CCNE1 and TPX2 were also considered conditions for the transformation of ovarian cancer [31].”
Background
HOXB9 Overexpression Confers Chemoresistance to Ovarian Cancer Cells by Inducing ERCC-1, MRP-2, and XIAP
Suh, D. H., Park, W. H., Kim, M., Kim, K., No, J. H., & Kim, Y. B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021249 · Cited by 9
“Ovarian cancer is characterized by its heterogeneity [25].”
BackgroundResult
MET overexpression in ovarian cancer via CD24 ‐induced downregulation of miR ‐181a: A signalling for cellular quiescence‐like state and chemoresistance in ovarian CSCs
Kwon, J. E., Jang, Y., Yun, B. S., Kang, S., Kim, Y. H., Kim, B. G., & Cho, N. H. (2023) · Cell Proliferation · doi:10.1111/cpr.13582 · Cited by 9
“34 The roles of MET in ovarian CSC phenotype manifestation have not been studied.”
Background
Molecular insights into the transcriptional regulatory role of thyroid hormones in ovarian cancer
Shinderman‐Maman, E., Weingarten, C., Moskovich, D., Werner, H., Hercbergs, A. A., Davis, P. J., Ellis, M. H., & Ashur‐Fabian, O. (2017) · Molecular Carcinogenesis · doi:10.1002/mc.22735 · Cited by 9
The Effect of Olaparib and Bortezomib Combination Treatment on Ovarian Cancer Cell Lines
Berkel, Ç., Küçük, B., Usta, M., Yılmaz, E., & Çaçan, E. (2020) · European Journal of Biology · doi:10.26650/eurjbiol.2020.0035 · Cited by 9
Effects of trans‑(±)‑kusunokinin on chemosensitive and chemoresistant ovarian cancer cells
Mad-adam, N., Rattanaburee, T., Tanawattanasuntorn, T., & Graidist, P. (2021) · Oncology Letters · doi:10.3892/ol.2021.13177 · Cited by 9
“A2780cis, SKOV‐3 and OVCAR‐3 are chemoresistant cells and are classified as EC, CC and HGSC in the epithelial ovarian cancer subtype, respectively (37,38).”
Background
TGF-β signaling proteins and CYP24A1 may serve as surrogate markers for progesterone calcitriol treatment in ovarian and endometrial cancers of different histological types
Paucarmayta, A., Taitz, H., Casablanca, Y., Rodriguez, G. C., Maxwell, G. L., Darcy, K. M., & Syed, V. (2019) · Translational Cancer Research · doi:10.21037/tcr.2019.07.36 · Cited by 9
Retracted
Characteristics of in vitro model systems for ovarian cancer studies
Tudrej, P., Kujawa, K. A., Cortez, A. J., & Lisowska, K. M. (2019) · Oncology in Clinical Practice · doi:10.5603/ocp.2019.0024 · Cited by 9
Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors: Implications for Combinations and Scheduling
Smith, H. L., Willmore, E., Mukhopadhyay, A., Drew, Y., & Curtin, N. J. (2022) · Cancers · doi:10.3390/cancers14225559 · Cited by 9
“These two well-characterised ovarian cancer cell lines of differing molecular pathologies [20,21] were selected because four of the five PARPi used in this study are approved in ovarian ca cer.”
Background
The Sall2 transcription factor promotes cell migration regulating focal adhesion turnover and integrin β1 expression
Riffo, E. N., Palma, M. S., Hepp, M. I., Benítez-Riquelme, D., Torres, V. A., Castro, A. F., & Pincheira, R. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1031262 · Cited by 8
“The A2780 ovarian cell line is associated with amoeboid migration, characterized by the ability tomove and invade independently of proteolysis by conferring increased motility and invasion of cells (Beaufort et al., 2014).”
Background
Three Dimensional Models of Endocrine Organs and Target Tissues Regulated by the Endocrine System
Luca, E., Zitzmann, K., Bornstein, S. R., Kugelmeier, P., Beuschlein, F., Nölting, S., & Hantel, C. (2023) · Cancers · doi:10.3390/cancers15184601 · Cited by 10
Serum starvation-based method of ovarian cancer cell dormancy induction and termination in vitro
Rutecki, S., Leśniewska-Bocianowska, A., Chmielewska, K., Matuszewska, J., Naumowicz, E., Uruski, P., Radziemski, A., Mikuła‐Pietrasik, J., Tykarski, A., & Książek, K. (2023) · Biology Methods and Protocols · doi:10.1093/biomethods/bpad029 · Cited by 8
“…results obtained using primary EOC cell cultures (high-grade serous histotype) and three established cell lines (A2780, OVCAR-3, and SKOV-3) differing in their genetic signatures (including P53 status), histological origin (endometrioid, clear cell, high-grade serous), and aggressiveness [22, 23].”
Background
Exploring the Potential of Natural Killer Cell-Based Immunotherapy in Targeting High-Grade Serous Ovarian Carcinomas
Kaur, K., Sanghu, J., Memarzadeh, S., & Jewett, A. (2024) · Vaccines · doi:10.3390/vaccines12060677 · Cited by 8
“…of peripheral blood-derived NK cells with a combination of IL-2 and anti-CD16 mAbs, and co-culturing of activated NK cells with osteoclasts (OCs) as feeder cells in the presence of probiotics sAJ2, this process leads to expansion and highly functional activation of NK cells [103,128,129].”
Background
Inhibition of Phospho-S6 Kinase, a Protein Involved in the Compensatory Adaptive Response, Increases the Efficacy of Paclitaxel in Reducing the Viability of Matrix-Attached Ovarian Cancer Cells
Choi, J. I., Park, S. H., Lee, H., Lee, D. W., & Lee, H. N. (2016) · PLoS ONE · doi:10.1371/journal.pone.0155052 · Cited by 8
“reported that the putative histology of SKOV3 was an endometrioid or clear cell type, the original histology is also a serous type [29].”
Background
Effect of IL-6 and IL-8 on the expression of the complement activation inhibitors MAC-inhibitory protein and decay-accelerating factor in ovarian cancer A2780 cells
Kapka‐Skrzypczak, L., Popek-Marciniec, S., Sawicki, K., Wolińska, E., Czajka, M., & Skrzypczak, M. (2016) · Oncology Letters · doi:10.3892/ol.2016.4795 · Cited by 8
Novel glycolipid agents for killing cisplatin-resistant human epithelial ovarian cancer cells
Moraya, A. I., Ali, J. L., Samadder, P., Liang, L., Morrison, L. C., Werbowetski‐Ogilvie, T. E., Ogunsina, M. O., Schweizer, F., Arthur, G., & Nachtigal, M. W. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0538-9 · Cited by 8
“There are few reliable models of drug-resistant EOC cells available for research [7, 12, 29].”
Background
NGF/TRKA Promotes ADAM17-Dependent Cleavage of P75 in Ovarian Cells: Elucidating a Pro-Tumoral Mechanism
Garrido, M. P., Vallejos, C., Girardi, S., Gabler, F., Selman, A., López‐Moncada, F., Vega, M., & Romero, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042124 · Cited by 8
Molecular Targeting of Notch Signaling Pathway by DAPT in Human Ovarian Cancer: Possible Anti Metastatic Effects
Akbarzadeh, M., Majidinia, M., Aval, S. F., Mahbub, S., & Zarghami, N. (2018) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2018.19.12.3473 · Cited by 8
“Epithelial ovarian cancer is the most lethal form in the world and OVCAR-3 cell line is a highly metastatic and drug-resistant human carcinoma cell line, thus it is an appropriate model system to study the effect and mechanisms of various anticancer agents (Beaufort et al., 2014).”
Background
Discovery of Steroidal Lactam Conjugates of POPAM-NH 2 With Potent Anticancer Activity
Trafalis, D. T., Dalezis, P., Geromichalou, E. G., Sagredou, S., Sflakidou, E., Voura, M., Grammatikopoulou, M., Gabriel, C., & Sarli, V. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0255 · Cited by 8
Advancing 3D Spheroid Research through 3D Scaffolds Made by Two-Photon Polymerization
Vitkūnaitė, E., Žymantaitė, E., Mlynska, A., Andrijec, D., Limanovskaja, K., Kaszynski, G., Matulis, D., Šakalys, V., & Jonušauskas, L. (2024) · Bioengineering · doi:10.3390/bioengineering11090902 · Cited by 8
“Said cell lines exhibit a different genetic background, morphology [49], and ability to form 3D cell cultures in a scaffold-free environment.”
Background
Novel p53 reactivators that are synergistic with olaparib for the treatment of gynecologic cancers with mutant p53
Smith, L. E., Padilla, J. L., Licor, A., Steinkamp, M. P., Lagutina, I. V., Guo, Y. P., Devor, E. J., Pankratz, V. S., Sallmyr, A., Oyebamiji, O., et al. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102522 · Cited by 7
“COV362 cells are an endometrioid subtype of high-grade serous ovarian adenocarcinoma with the missense mutation Y220C in p53 [36].”
Single-cell characterization of step-wise acquisition of carboplatin resistance in ovarian cancer
Wenzel, A. T., Champa, D., Venkatesh, H., Sun, S., Tsai, C., Mesirov, J. P., Bui, J. D., Howell, S. B., & Harismendy, O. (2022) · npj Systems Biology and Applications · doi:10.1038/s41540-022-00230-z · Cited by 10
“Additionally, CAOV3 has been unambiguously characterized as a serous ovarian cancer cell line in contrast to other models of platinum resistance such as A2780 27 .”
Result
Clinically Informed Intelligent Classification of Ovarian Cancer Cells by Label‐Free Holographic Imaging Flow Cytometry
Pirone, D., Cavina, B., Sirico, D. G., Mugnano, M., Bianco, V., Miccio, L., Perrone, A. M., Porcelli, A. M., Gasparre, G., Kurelac, I., et al. (2024) · Advanced Intelligent Systems · doi:10.1002/aisy.202400390 · Cited by 7
The cyclin‐dependent kinase inhibitor AT7519 augments cisplatin's efficacy in ovarian cancer via multiple oncogenic signaling pathways
Wang, L., Chen, Y. X., Li, H., Xu, Q., & Liu, R. (2021) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12709 · Cited by 7
“Six ovarian cancer cell lines are derived from patients with different disease stages and molecular subtypes, but all are epithelial morphology [13].”
Background
Abdominal tissue concentrations and penetration of carboplatin in a HIPEC procedure ‒ assessment in a novel porcine model
Petersen, E. K., Bue, M., Harlev, C., Jørgensen, A. R., Schmedes, A., Hanberg, P., Petersen, L. K., & Stilling, M. (2022) · Pleura and Peritoneum · doi:10.1515/pp-2022-0110 · Cited by 7
Targeting estrogen metabolism in high-grade serous ovarian cancer shows promise to overcome platinum resistance
Marolt, N., Pavlič, R., Kreft, T., Gjorgoska, M., & Rižner, T. L. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117069 · Cited by 7
Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line
Teng, P.-N., Bateman, N. W., Wang, G., Litzi, T. A., Blanton, B. E., Hood, B. L., Conrads, K. A., Ao, W., Oliver, K., Darcy, K. M., et al. (2017) · Human Cell · doi:10.1007/s13577-017-0162-1 · Cited by 7
“Overexpressed genes in the spindle-like cluster are associated with cell movement, invasion and epithelial mesenchymal transition (EMT) [17].”
BackgroundMethodInfluential
Genome-wide DNA copy number analysis in clonally expanded human ovarian cancer cells with distinct invasive/migratory capacities
Li, L., Bai, H., Yang, J., Cao, D., & Shen, K. (2017) · Oncotarget · doi:10.18632/oncotarget.14767 · Cited by 7
“com/oncotarget with predominant expression of mesenchymal markers [37].”
Background
Cucurbitacin-I exhibits anticancer activity by inducing apoptosis in SKOV3 human ovarian cancer cells
Park, J.-W., Kim, S. M., Lee, S. Y., Park, S.-W., & Kim, J. (2024) · Molecular & Cellular Toxicology · doi:10.1007/s13273-024-00451-9 · Cited by 6
“These cells are resistant to tumor necrosis factor and other cytotoxic drugs such as diph-theria toxin, cisplatin, and adriamycin (Beaufort et al. 2014; Ramalingam 2016).”
VERU-111, an orally available tubulin inhibitor, suppresses ovarian tumor growth and metastasis
Waddell, S., Zhao, G., Liu, Z., Chen, H., Zhang, W., Wang, Y., Miller, D. D., Yue, J., & Li, W. (2024) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.124.002298 · Cited by 6
“SKOV3 is representative of nonserous ovarian carcinoma subtypes, which account for 25% of epithelial ovarian cancers (Domcke et al, 2013; Beaufort et al, 2014).”
Development of a Bioluminescent BRCA1-Deficient Xenograft Model of Disseminated, High-Grade Serous Ovarian Cancer
Shen, Y. T., Wang, L. L., Evans, J. C., Allen, C. J., & Piquette‐Miller, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102498 · Cited by 6
“However, recent analyses of these cell lines demonstrate genetic and histological deviations from that which is seen clinically [13,14].”
Background
Identification of Key Factors Associated with Early- and Late-Onset Ovarian Serous Cystadenocarcinoma
Ma, S., Zheng, Y., & Fei, C. (2020) · Future Oncology · doi:10.2217/fon-2020-0668 · Cited by 6
Long Noncoding RNA E2F4as Promotes Progression and Predicts Patient Prognosis in Human Ovarian Cancer
Park, S., Kim, L. K., Kim, Y. T., Heo, T., & Kim, H. J. (2020) · Cancers · doi:10.3390/cancers12123626 · Cited by 6
“The subtypes of the epithelial ovarian cancer cell lines are as follows: SKOV3, serous; TOV112D, endometrioid; A2780, non-specified; OVCAR3, carcinoma; OVCA429, serous; and OVCA433, serous [29].”
Background
Differential histone deacetylase inhibitor‐induced perturbations of the global proteome landscape in the setting of high‐grade serous ovarian cancer
Duda, J. M., Twigg, C. A. I., & Thomas, S. N. (2022) · PROTEOMICS · doi:10.1002/pmic.202100372 · Cited by 6
“CAOV3 cells uniquely contain an EGFR mutation that is not found in the other two cell lines in this analysis [33].”
Background
Biological and clinical impact of membrane EGFR expression in a subgroup of OC patients from the phase IV ovarian cancer MITO-16A/MANGO-OV2A trial
Forlani, L., Cecco, L. D., Simeon, V., Paolini, B., Bagnoli, M., Cecere, S. C., Spina, A., Citeroni, E., Bignotti, E., Lorusso, D., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02651-y · Cited by 7
“6 A Western blotting for EGFR and AXL expressions in lysates from OC cell lines representative of HGSOCs or non-HGSOCs cell lines [34].”
Background
Clinical importance of the EMSY gene expression and polymorphisms in ovarian cancer
Dansonka‐Mieszkowska, A., Szafron, L. M., Moes-Sosnowska, J., Kulińczak, M., Balcerak, A., Konopka, B., Kulesza, M., Budziłowska, A., Łukasik, M., Piekarska, U., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24878 · Cited by 6
“The differential response to the drug may be related to different genetic aberrations harbored by each of the cell lines [27, 28].”
Background
RUNX3 Transcript Variants Have Distinct Roles in Ovarian Carcinoma and Differently Influence Platinum Sensitivity and Angiogenesis
Heinze, K., Hölzer, M., Ungelenk, M., Gerth, M., Thomale, J., Heller, R., Morden, C. R., McManus, K. J., Mosig, A. S., Dürst, M., et al. (2021) · Cancers · doi:10.3390/cancers13030476 · Cited by 6
“Cell line authentication was done by STR profiling and revealed the correct identity depicted by 97% and 100% percent match for A2780 and OVCAR3 (ICLAC match criteria worksheet [38]) compared to STR reference profiles (ATCC and [35]).”
Result
Computer-aided drug discovery of a dual-target inhibitor for ovarian cancer: therapeutic intervention targeting CDK1/TTK signaling pathway and structural insights in the NCI-60
Tang, S., Sumitra, M. R., Kuo, Y.-C., Hsu, H.-L., Ansar, M., Huang, S., Lee, S., Wang, H.-J., Lawal, B., Wu, A. T. H., et al. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.110445 · Cited by 6
Identification of pyrazolo-piperidinone derivatives targeting YAP-TEAD interface 3 as anticancer agents through integrated virtual screening and mass spectrometry proteomics
Scalvini, L., Tagliazucchi, L., Elisi, G. M., Zappaterra, D., Moschella, M. G., Fantini, S., Aiello, D., Guerrini, R., Albanese, V., Pacifico, S., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118056 · Cited by 5
The adaptor protein VEPH1 interacts with the kinase domain of ERBB2 and impacts EGF signaling in ovarian cancer cells
Kollara, A., Burt, B. D., Ringuette, M. J., & Brown, T. J. (2023) · Cellular Signalling · doi:10.1016/j.cellsig.2023.110634 · Cited by 5
Elevated Levels of Lamin A Promote HR and NHEJ-Mediated Repair Mechanisms in High-Grade Ovarian Serous Carcinoma Cell Line
Sengupta, D., Mukhopadhyay, A., & Sengupta, K. (2023) · Cells · doi:10.3390/cells12050757 · Cited by 4
Enhanced anticancer effect of thymidylate synthase dimer disrupters by promoting intracellular accumulation
Marverti, G., Moschella, M. G., Belardo, A., Lamesta, M., Mercanile, G., Tagliazucchi, L., Aiello, D., Venturelli, A., Illuminati, D., Guerrini, R., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1477318 · Cited by 5
Drug repurposing screen targeting PARP identifies cytotoxic activity of efavirenz in high-grade serous ovarian cancer
Matthews, B., Wong‐Brown, M. W., Liu, D., Yee, C., Dickson, K.-A., Schneider, J., Islam, S., Head, R. J., Martin, J. H., Ford, C. E., et al. (2024) · Molecular Therapy Oncology · doi:10.1016/j.omton.2024.200911 · Cited by 5
IMGN853 Induces Autophagic Cell Death in Combination Therapy for Ovarian Cancer
Chelariu-Raicu, A., Vu, T. C., Umamaheswaran, S., Stur, E., Hanjra, P., Han, Y., Hu, M., Lin, J., Lawson, B. C., Liu, J., et al. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0215 · Cited by 5
“12] to represent the different subtypes of ovarian cancer in this study.”
Recent Approaches Encompassing the Phenotypic Cell Heterogeneity for Anticancer Drug Efficacy Evaluation
Stulpinas, A., Imbrasaitė, A., Krestnikova, N., & Kalvelytė, A. V. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.89395 · Cited by 7
“Similar work was done with 100 ovarian cancer cell lines to make an OCCP panel where the cells were described [170].”
Result

Authors: Beaufort, C. M., Helmijr, J. C. A., Piskorz, A. M., Hoogstraat, M., Ruigrok-Ritstier, K., Besselink, N., Murtaza, M., van IJcken, W. F. J., Heine, A. A. J., Smid, M., Koudijs, M. J., Brenton, J. D., Berns, E. M. J. J., & Helleman, J.
Affiliations: Erasmus MC Cancer Institute (NL)
University of Cambridge (GB)
University Medical Center Utrecht (NL)
Corresponding author: Berns, Els M. J. J.
ORCID: Helmijr, Jean C. A.
Piskorz, Anna M.
Hoogstraat, Marlous
Besselink, Nicolle
Murtaza, Muhammed
Smid, Marcel
Brenton, James D.
Helleman, Jozien
Venue: PLoS ONE
Publisher: Public Library of Science (PLoS)
Published: 2014-09-17
Volume: 9
Issue: 9
Pages: e103988
ISSN: 1932-6203 (ISSN-L)
DOI: 10.1371/journal.pone.0103988
PMC: PMC4167545
OpenAlex: W2015030879
Cited by: 403
References: 89
Citations by year: 2026: 15 · 2025: 24 · 2024: 30 · 2023: 48 · 2022: 38 · 2021: 54 · 2020: 52 · 2019: 41 · 2018: 27 · 2017: 28 · 2016: 25 · 2015: 21
FWCI: 29.95
Type: journal article
Language: en
Update notices: correction (2015-03-23)
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0/ (unspecified)
Locations: PLoS ONE (publishedVersion, cc-by)
Europe PMC (PubMed Central) (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Figshare (submittedVersion, cc-by)
RePub (Erasmus University Rotterdam) (submittedVersion)
Funders: Cancer Research UK (15601)
Universitair Medisch Centrum Utrecht
Topics: Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
Keywords: epithelial ovarian cancer, ovarian cancer cell lines, morphological subtypes, high-grade serous carcinoma, low-grade serous carcinoma, tumor heterogeneity, metastasis, prognosis, drug response, preclinical models
MeSH terms: Carcinoma, Ovarian Epithelial, Female, Humans, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Gene Expression Regulation, Neoplastic, MicroRNAs

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks